School shot reminders improve vax rates; HPV uptake drop in girls & young women;

> Kids getting vax reminders from school-based health centers (SBHCs) and from private clinics had better rates of vaccinations, according to two studies published in Pediatrics. Press release | School abstract | Clinic abstract

> The numbers of girls and young women completing a course of the HPV vaccine has dropped by as much as 63% since the vaccine was approved in 2006. Press release

> Genome-wide screening of viruses could speed vax R&D. Press release | Abstract

> Following its withdrawal of a $65 million initial public offering, immunotherapy company Argos Therapeutics has raised a $25 million round in funding to support a Phase III clinical trial of its kidney cancer immunotherapeutic. Article

> The International AIDS Vaccine Initiative (IAVI), GlycoMimetics, and Glycosensors and Diagnostics are working together to develop an HIV/AIDS vaccine based on glycomimetics. Press release

> Australian vaccine company BioDiem is collaborating with French biopharma company VIVALIS to combine BioDiem's proprietary virus, LAIV, and VIVALIS' proprietary cell line, EB66. Press release

> GenVec has received a Phase I SBIR grant from the NIAID to fund development of its RSV vaccine program. Press release

> Aeras and IDRI are going to codevelop IDRI's vaccine candidate against active and latent tuberculosis; there is a Phase I trial planned for 2012. Press release

> Aeras is working with Chinese company Tianjin CanSino Biotechnology to develop CanSino's tuberculosis vaccine candidate, Ad5Ag85A; this is currently in Phase I in China. Press release

> Cuba will begin a clinical trial of a locally-developed pneumococcal vaccine in 2012. Article

> Novavax has launched enrollment of a second Phase I bird flu vaccine trial in the U.S. only a week after the launch of its first trial. Press release

> The Colombian government is supporting development of a malaria vaccine. Article

> iBio ($IBIO) has been granted a U.S. patent for its iBioModulator platform, which modifies the immune response to a vaccine. Press release

> Profectus BioSciences has received an NIH grant to develop a vaccine against Nipah or Hendra virus infection. Press release

> Chinese researchers suggest combining synthetic carbohydrate vaccines with cancer cell glycoengineering for effective cancer immunotherapy. Abstract

And Finally… University of Rochester Medical Center is looking for 20 volunteers for LigoCyte Pharmaceuticals' stomach flu shot trial. Press release

Suggested Articles

Daiichi Sankyo says it still unable to fulfill a government mandate to be able to produce enough H5N1 flu vaccine to fight an epidemic in Japan.

GSK’s Shingrix has continuously impressed industry watchers with its growth, and the company just added another large market to its list: China.

WuXi Biologics says it will build a dedicated facility to manufacture a commercial vaccine product for a client in a $3 billion contract.